Download MendeleyEnzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.
Trivella, D.B., Pereira, A.R., Stein, M.L., Kasai, Y., Byrum, T., Valeriote, F.A., Tantillo, D.J., Groll, M., Gerwick, W.H., Moore, B.S.(2014) Chem Biol 21: 782-791
- PubMed: 24930969
- DOI: https://doi.org/10.1016/j.chembiol.2014.04.010
- Primary Citation of Related Structures:
4HNP, 4HRC, 4HRD, 4LTC - PubMed Abstract:
Hydroamination reactions involving the addition of an amine to an inactivated alkene are entropically prohibited and require strong chemical catalysts. While this synthetic process is efficient at generating substituted amines, there is no equivalent in small molecule-mediated enzyme inhibition. We report an unusual mechanism of proteasome inhibition that involves a hydroamination reaction of alkene derivatives of the epoxyketone natural product carmaphycin. We show that the carmaphycin enone first forms a hemiketal intermediate with the catalytic Thr1 residue of the proteasome before cyclization by an unanticipated intramolecular alkene hydroamination reaction, resulting in a stable six-membered morpholine ring. The carmaphycin enone electrophile, which does not undergo a 1,4-Michael addition as previously observed with vinyl sulfone and α,β-unsaturated amide-based inhibitors, is partially reversible and gives insight into the design of proteasome inhibitors for cancer chemotherapy.
Organizational Affiliation:
Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California at San Diego, La Jolla, CA 92093-0212, USA; Institute of Chemistry, University of Campinas, Campinas SP 13083-970, Brazil; Brazilian Biosciences National Laboratory, National Center for Research in Energy and Materials, Campinas SP 13083-970, Brazil.
